Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Arizona Compound Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield of ArizonaPolicy N/A

    Compound Medication - Non-Formulary (Affordable Care Act (ACA) Plans)

    Customize your policy alerts

    Sign up for all blue cross blue shield - arizona policy alerts

    Know when blue cross blue shield - arizona releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Establishes medical necessity and prior authorization requirements for non-formulary compounded medications under Blue Cross Blue Shield of Arizona Commercial and Marketplace plans; excludes Federal Employee Program, Medicare Advantage, Medicaid, and out-of-state Blue Cross and Blue Shield members.

    Policy Summary
    PayerBlue Cross Blue Shield of Arizona
    PolicyCompound Medication - Non-Formulary (Affordable Care Act (ACA) Plans)
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a complete prior authorization request with the signed form, chart notes, laboratory results, and supporting clinical documentation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Commercial and MarketplaceApplicable plan types
    3Generic equivalents required when available
    3 months eachGeneric trial duration
    At least 1Federal legend drugs required

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Retail onlyDispensing location
    NoMail order availability

    Coverage Criteria

    Initial Therapy

    Covered for initial therapy when ALL of the following are met:

    ALL of the following

    • The compound is prescribed by a licensed healthcare provider.
    • The diagnosis is clearly specified.
    • Use is consistent with the FDA-approved label.
    • The compound prescription meets ALL of the following

      • ONE of the following

        • The requested compound is not commercially available in the same dosage form, route of administration, or requested dose from any pharmaceutical manufacturer.
        • The compound contains an ingredient that is in short supply.
        • Due to severe intolerance or severe hypersensitivity to inactive ingredient(s), the compound must be prepared without one or more inactive ingredients, such as dyes, preservatives, sugars, or flavoring.

          Documentation of the intolerance or hypersensitivity must be submitted with the request.

        • There is a need for a unique dosage form or concentration due to age, weight, or inability to take a solid dosage form.
      • For ingredient(s) that normally require prior authorization, all criteria for prior authorization of the ingredient(s) are met.
      • The compound contains at least one federal legend drug.
      • Active ingredients are FDA approved or supported by national compendia or peer-reviewed literature for the diagnosis, route of delivery, therapeutic amounts, safety and effectiveness, and proposed duration of therapy.
    • Medical necessity or justification for use is submitted with the request.
    • Treatment goals and proposed duration of use are included in the request.
    • The request follows the plan-specific Benefit Design.
    • The use is not for cosmetic purposes and is not considered manufacturing or distribution.

    Continuation Therapy

    Covered for continuation therapy when ALL of the following are met:

    ALL of the following

    • The member continues to be seen by a licensed healthcare provider.
    • Treatment goals specified in the original request have been achieved and are maintained.
    • The request is for the same compound as originally approved, including the same dosage form, strength, ingredients, and other applicable characteristics.
    • ALL of the following clinical response requirements are met

      • The condition has not progressed or worsened.
      • There is evidence of efficacy, disease stability, or improvement.

    Brand-Specific Criteria

    When a brand-name product is requested and generic equivalents are available, ALL of the following are required:

    ALL of the following

    • There has been failure, contraindication, or intolerance with THREE generic equivalents, if available, for at least three months each.

      Any failure, contraindication, or intolerance to the generic drugs should be reported to the FDA; see the Definitions section.

    Non-Formulary Medication Exception

    A non-formulary compound medication is covered under the ACA Pharmacy Benefit only when BCBSAZ authorizes a formulary exception.

    ALL of the following

    • The medication is not included on the Formulary and is otherwise not covered under the ACA Pharmacy Benefit.
    • The member asks the prescribing provider to request that BCBSAZ make a Formulary Exception for the non-formulary medication.
    • BCBSAZ authorizes the Formulary Exception.

    Ingredients must not be any of the following: used for a non-FDA-approved use for the diagnosis; investigational or experimental; not FDA approved for compounding; removed from the market due to safety or effectiveness concerns; or compounded for convenience.

    Use is not for cosmetic purposes and is not considered manufacturing or distribution.

    Ingredients must not be used for a non-FDA-approved use for the diagnosis, be investigational or experimental, be not FDA approved for compounding, have been removed from the market due to safety or effectiveness concerns, or be compounded for convenience. There must be no new contraindications or exclusions to continued use.

    Bulk chemicals, medical food supplements, and nutritional additives that are not approved for dispensing by prescription are not considered federal legend drugs and are excluded from coverage as compound medications.

    Compound medications are not available through the mail order pharmacy benefit.

    Medications not included on the Formulary are not covered under the ACA Pharmacy Benefit unless BCBSAZ authorizes an exception. Members may ask the prescribing provider to request that BCBSAZ make a Formulary Exception for a non-formulary medication. BCBSAZ decides which medications are non-formulary and whether to authorize Formulary Exceptions.

    Provider Actions and Coverage Risks

    Prior Authorization

    Complete Prior Authorization Request

    Submit a complete prior authorization request for medications requiring authorization. The prescribing provider must sign the request and include the completed form, chart notes, laboratory workup, and all other supporting clinical documentation.

    Prior Authorization

    Meet Ingredient-Specific Authorization Criteria

    For each ingredient that normally requires prior authorization, satisfy all applicable prior authorization criteria before coverage can be considered.

    Prior Authorization

    Formulary Exception Required

    Because compound medications are non-formulary for BCBSAZ ACA plans, submit and obtain BCBSAZ authorization for a formulary exception before coverage.

    Background

    Compounded medications are custom-mixed by a pharmacist or other qualified healthcare professional to address an individual patient's clinically supported need. Coverage is intended for situations in which a commercially available product cannot meet the need in the same dosage form, route of administration, or dose. The compound must contain at least one federal legend drug in therapeutic amounts, with the active ingredients and proposed use supported by applicable clinical evidence.

    Definitions

    Compound medication
    DefinitionA medication containing at least one FDA-approved prescription component in therapeutic amounts that is custom-mixed by a pharmacist or other healthcare professional for an individual patient's needs.
    Availability requirementThe medication is not commercially available in the requested dosage form, route, or dose.
    Federal legend drug requirementThe compound must contain at least one federal legend drug in therapeutic amounts.
    Federal legend drug
    DefinitionA medication product that federal law prohibits dispensing without a prescription.
    Prescription requirementThe medication may be dispensed only with a prescription under federal law.

    Initial Therapy Criteria

    Initial Therapy

    Initial therapy requires satisfaction of all applicable prescriber, indication, compounding-need, ingredient, safety, documentation, and benefit-design requirements.

    Initial compounded-medication criteria

    • Qualifying compounding need: At least one of the following applies: the compound is not commercially available in the same dosage form, route of administration, or requested dose; an ingredient is in short supply; inactive ingredients must be removed because of severe intolerance or severe hypersensitivity; or a unique dosage form or concentration is needed because of age, weight, or inability to take a solid dosage form.At least 1 of 4
    • Prescriber and indication: The compound is prescribed by a licensed healthcare provider for a clearly specified diagnosis.
    • Age and ingredient support:

    Continuation Criteria

    Continuation Therapy and Renewal

    Continuation therapy and renewal require all listed clinical, prescriber, adherence, safety, and documentation conditions to be met.

    Continuation therapy and renewal

    • Prescriber and clinical response: The member continues to be seen by a licensed healthcare provider, and treatment goals specified in the original request have been achieved and maintained.
    • Same compound: The request is for the same compound as originally approved, including the same dosage form, strength, ingredients, and other relevant characteristics.
    • Disease response and safety: The condition has not progressed or worsened; there is evidence of efficacy, disease stability, or improvement; there are no significant unacceptable adverse drug reactions; and no new contraindications or exclusions to continued use are present.

    Step Therapy

    StepRequirementTrial duration
    1Try three generic equivalents, when available, before coverage of the brand-specific compound or ingredient.At least 3 months for each generic equivalent
    StepCoverage requirementDocumentation
    1Document failure, contraindication, or intolerance with three generic equivalents, when available.Each generic equivalent must have been tried for at least 3 months; report failure, contraindication, or intolerance to the FDA.

    Site of Care

    Billing Rule

    Use a credentialed retail pharmacy

    An approved compounded medication must be obtained from a retail pharmacy credentialed to dispense compounded medications. Compounded medications are not available through the mail order pharmacy benefit.

    Policy Summary
    PayerBlue Cross Blue Shield of Arizona
    PolicyCompound Medication - Non-Formulary (Affordable Care Act (ACA) Plans)
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a complete prior authorization request with the signed form, chart notes, laboratory results, and supporting clinical documentation.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and Coverage RisksBackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaStep TherapySite of Care
  1. There are no significant unacceptable adverse drug reactions.
  2. Adherence to the prescribed therapy regimen has been documented.
  3. There are no new contraindications or exclusions to continued use.
  4. Prior Authorization

    Exception Authorization Required

    Obtain BCBSAZ authorization for the non-formulary compound. Without an authorized exception, the compound is not covered under the ACA Pharmacy Benefit.

    Step Therapy

    Document Three Generic-Equivalent Trials

    For a brand-specific request, document failure, contraindication, or intolerance with three generic equivalents, when available, for at least three months each.

    • Report failure, contraindication, or intolerance to the FDA as applicable.
    Step Therapy

    Three Generic Equivalents Before Brand Coverage

    Before requesting brand coverage, document failure, contraindication, or intolerance with three available generic equivalents for at least three months each.

    • Report applicable generic-drug failure, contraindication, or intolerance to the FDA.
    Prior Authorization

    Prior Authorization Submission

    Submit the completed prior authorization request form with the required supporting clinical records. The prescribing provider must sign the form.

    • Include chart notes, laboratory results, and supporting clinical documentation.
    Documentation Required

    Provide Diagnosis and Clinical Support

    Clearly specify the diagnosis and support the compound's active ingredients, route of delivery, therapeutic amounts, safety and effectiveness, and proposed duration of therapy.

    Documentation Required

    Document Inactive-Ingredient Intolerance

    When severe intolerance or severe hypersensitivity to inactive ingredients is the reason for compounding, document the intolerance or hypersensitivity and why the compound must omit those ingredients.

    • Examples include dyes, preservatives, sugars, and flavoring.
    Denial Risk

    Samples Are Not Treatment Evidence

    Do not use patient samples as evidence of an initial treatment course, continuation of therapy, or adequate trial and failure.

    Documentation Required

    Initial Request Documentation

    For an initial request, submit the completed request form and all required clinical documentation.

    • Include chart notes, laboratory results, and supporting clinical documentation.
    Documentation Required

    Continuation Documentation

    For continuation or renewal, submit documentation showing improvement for the indication, laboratory values confirming safe use, and supporting clinical records.

    • Include chart notes and evidence of improvement.
    Prior Authorization

    Request a Formulary Exception

    A member may ask the prescribing provider to request a formulary exception for a non-formulary medication. BCBSAZ determines whether to authorize the exception.

    Denial Risk

    Establish a Qualifying Compounding Need

    Coverage may be denied when the compound is commercially available in the same dosage form, route, or dose, or when another qualifying compounding need is not established.

    • Other qualifying needs may include a shortage, severe inactive-ingredient intolerance or hypersensitivity, or a unique dosage form or concentration.
    Denial Risk

    Ingredient Authorization Criteria Not Met

    Coverage may be denied when an ingredient requiring prior authorization does not meet all applicable ingredient-specific authorization criteria.

    Denial Risk

    Meet Ingredient and Evidence Requirements

    The compound must contain at least one federal legend drug, and active ingredients must have FDA approval or support from national compendia or peer-reviewed literature for the diagnosis, route, therapeutic amounts, safety and effectiveness, and proposed duration.

    Denial Risk

    Avoid Unsafe or Unsupported Compounding

    Coverage may be denied for unsafe or unsupported compounding, including ingredients that are non-FDA-approved for compounding, investigational, experimental, removed from the market for safety or effectiveness concerns, or used for convenience.

    Denial Risk

    Meet Additional Coverage Conditions

    Coverage may be denied when required medical necessity or justification, treatment goals, proposed duration, benefit-design conditions, or other additional requirements are not satisfied.

    • The use must not be cosmetic or constitute manufacturing or distribution.
    Denial Risk

    Document Generic Trials for Brand Requests

    A brand-specific request may be denied unless failure, contraindication, or intolerance with three generic equivalents is documented when generic equivalents are available, with each trial lasting at least three months.

    Denial Risk

    No Authorized Formulary Exception

    Non-formulary compounds are not covered under the ACA Pharmacy Benefit unless BCBSAZ authorizes a formulary exception.

    • If approved, the compound must be obtained from a credentialed retail pharmacy; it is not available through the mail-order pharmacy benefit.
    Denial Risk

    Prohibited or Unsafe Ingredients

    Denial risk applies to prohibited or unsafe ingredients, including investigational or experimental ingredients, ingredients not FDA-approved for compounding, ingredients removed from the market for safety or effectiveness concerns, and ingredients compounded for convenience.

    Denial Risk

    Monitor for New Contraindications or Exclusions

    Continuation coverage may be denied if a new contraindication or exclusion to continued use arises.

    Note

    Route Off-Label Requests to the Separate Guideline

    Requests for non-FDA use or indication, or for dosing, frequency, or duration outside FDA-approved guidelines, must be evaluated under the applicable separate off-label use guideline.

    • Use the Off-Label Use of Non-Cancer Medications or Off-Label Use of Cancer Medications guideline, as applicable.
    Denial Risk

    Non-Formulary Medication Without Exception

    Coverage may be denied for a non-formulary medication when BCBSAZ has not authorized a formulary exception.

    Excluded productsBulk chemicals, medical food supplements, and nutritional additives not approved for dispensing by prescription are not considered federal legend drugs.
    Formulary Exception
    DefinitionA BCBSAZ authorization for coverage of a medication that is not on the ACA Pharmacy Benefit formulary.
    Coverage effectThe authorization permits coverage of a Non-Formulary Medication for a member.
    Decision-makerBCBSAZ decides whether to authorize Formulary Exceptions for coverage of Non-Formulary Medications.
    Non-Formulary Medication
    DefinitionA medication not included on the BCBSAZ ACA pharmacy formulary.
    Default coverage statusThe medication is not covered under the ACA Pharmacy Benefit.
    Exception pathwayCoverage requires BCBSAZ authorization of a Formulary Exception.
    Non-Formulary Medication
    DefinitionA medication that is not included on the ACA Pharmacy Benefit formulary.
    Coverage statusThe medication is not covered under the ACA Pharmacy Benefit unless BCBSAZ authorizes an exception.
    Formulary determinationBCBSAZ decides which medications are Non-Formulary under the ACA Pharmacy Benefit.
    Formulary Exception
    DefinitionAn authorization issued by BCBSAZ that permits coverage of a non-formulary medication under the ACA Pharmacy Benefit.
    Required actionThe prescribing provider may request that BCBSAZ make a Formulary Exception for a Non-Formulary Medication.
    Authorization authorityBCBSAZ decides whether to authorize Formulary Exceptions for Non-Formulary Medications.
    Use is consistent with the FDA-approved label, and active ingredients are FDA approved or supported by national compendia or peer-reviewed literature for the diagnosis, route of delivery, therapeutic amounts, safety and effectiveness, and proposed duration of therapy.
  5. Composition and prior authorization: The compound contains at least one federal legend drug, and all applicable prior authorization criteria are met for ingredients that normally require prior authorization.At least 1 federal legend drug
  6. Brand-specific criteria when applicable: The member has failure, contraindication, or intolerance with three generic equivalents when available, with each generic used for at least three months.3 generic equivalents; 3 months each
  7. Safety and additional requirements: No ingredient is used for a non-FDA-approved diagnosis, is investigational or experimental, is not FDA approved for compounding, was removed from the market because of safety or effectiveness concerns, or is compounded for convenience. Medical necessity or justification, treatment goals, and proposed duration of use are submitted; the request follows the plan-specific benefit design; use is not cosmetic; and use is not considered manufacturing or distribution.
  8. Initial Therapy and Formulary Exception

    Initial coverage requires the clinical criteria and a BCBSAZ Formulary Exception for the non-formulary compounded medication.

    Initial therapy and formulary exception: The compound meets the applicable initial therapy, composition, clinical-support, safety, and benefit-design requirements; a completed request form with chart notes, laboratory results, and supporting clinical documentation is submitted; and BCBSAZ authorizes a Formulary Exception for the non-formulary medication.Approval duration: 6 months or end of plan year

    If approved, the compound must be obtained from a retail pharmacy credentialed to dispense compounded medications.

    Initial Formulary Exception

    A non-formulary compound medication may be covered only when BCBSAZ authorizes a formulary exception.

    Initial formulary exception: The prescribing provider requests a Formulary Exception and BCBSAZ authorizes coverage of the non-formulary compound medication.

    The medication is not covered under the ACA Pharmacy Benefit unless the exception is authorized.

  9. Adherence to the prescribed therapy regimen has been documented.
  10. Documentation: The renewal request includes chart notes, supporting clinical documentation showing improvement in the indication, and laboratory values confirming safe use.
  11. Ingredient safety: Ingredients are not used for a non-FDA-approved diagnosis, investigational or experimental purposes, a use not FDA approved for compounding, or a use involving an ingredient removed from the market because of safety or effectiveness concerns; and the compound is not prepared for convenience.